Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment.
The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Keytruda.